Badania i konflikt interesow

Liczba wypowiedzi w tym wątku: 1

1. Data: 2002-03-03 03:25:59

Temat: Badania i konflikt interesow
Od: <b...@o...com.au> szukaj wiadomości tego autora

Ponizej zalaczam artykul z JAMA February 6, 2002;287:612-617.
Dobre angielskie translatory powinny to przetlumaczyc :

====================================================
=====================
Most Doctors Who Set Guidelines Have Industry Ties

The vast majority of doctors involved in establishing national guidelines on
disease treatment have financial ties to the pharmaceutical industry that
could potentially sway their recommendations and inappropriately influence
thousands of other physicians.

Eighty-seven percent of guideline authors had some type of relationship with
drug companies, yet these often were not disclosed, according to survey
responses from 100 authors of guidelines published from 1991 to 1999 for
common diseases such as diabetes, high blood pressure and asthma.

More specifically, 38% of respondents said they had served as employees or
consultants for pharmaceutical companies and 58% had received financial
support for medical research. In addition, 59% had links with drug companies
whose medications were considered in the particular guidelines they authored.

The findings show that people who work on committees who write practice
guidelines have lots of financial relationships with companies whose products
they're assessing.

And these figures may underestimate the problem, the researchers said, because
only 52% of the authors contacted for the survey responded.

Some may have declined to participate because they did not want to disclose
their industry relationships, the report indicates. Though the investigators
did not name names, the survey did not explicitly guarantee anonymity.

While industry ties don't necessarily mean that a doctor can't provide an
objective opinion, it's a potential problem.

In the study, the researchers did not actually search for concrete examples in
which industry ties translated into improper treatment recommendations. But,
when respondents were asked whether relationships with drug companies
influenced guideline recommendations, 19% said they thought their co-authors'
recommendations were swayed by their relationships and 7% said they thought
their own relationships influenced recommendations.

Industry relationships are often an essential part of doing business for
doctors. Many of the nation's top medical researchers at prestigious academic
institutions -- the same ones sought for guideline authorship -- have industry
relationships because it is the pharmaceutical companies who finance most of
the nation's drug research.

So, how much industry involvement should disqualify a doctor from
participation in clinical guidelines? That's the $64,000 question. Any cut
point would be considered arbitrary with the possible exception of zero
involvement.

The researchers specifically recommended the disqualification of authors who
own equity in a company whose products are being reviewed in the guidelines.

Beyond that, each medical group that sets guidelines should devise their own
ways for identifying and dealing with potential conflicts of interest within
their specialty -- ways they can preclude these conflicts from harming the
consumer.
====================================================
============

Jurek

--
Wysłano z serwisu OnetNiusy: http://niusy.onet.pl